Does Flushing the Uterine Cavity With Follicular Fluid After Ovum Pick-up Improve Implantation Rates in ICSI Cycles?

NCT ID: NCT01563822

Last Updated: 2012-10-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Traditionally during ovum pick-up in ICSI, we aspirate the follicles for oocyte retrieval but unfortunately we don't make use of the follicular fluid (FF) and we discard it in spite of the fact that this does not happen in nature. The fallopian tube picks-up the FF with the oocyte during ovulation. As this fluid contains stem cell factor and C-Kit receptor responsible for implantation and IGF responsible for endometrial growth and TGF that improves implantation. That's why flushing the endometrial cavity with FF after ovum pick-up might improve endometrial receptivity and implantation rates; the limiting step in ICSI.

Patients and Methods:

100 patients attending kasr El-Aini IVF center preparing for ICSI cycles are randomized into two groups. In the study group, flushing the endometrial cavity with 2ml of clear follicular fluid surrounding mature oocytes through an IUI catheter is done after ovum pick-up While in the control group, no flushing of the endometrial cavity with FF is done. The implantation rates and pregnancy rates in both groups will be assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction:

Looking at the process of IVF, we found that we only make use of the ovum and sperm and we neglect completely the valuable effect of the follicular fluid which is currently attracting a lot of attention. Several studies revealed a pivotal role played by this fluid in the process of fertilization and implantation as it is rich in growth factors as stem cell factor, transforming growth factor and insulin growth factor and cytokines (1,2).

Macciò study confirmed that follicular fluid (FF) contains factors that induce immunosuppression and explained that the immunosuppressive activity of FF is mediated by the specific inhibition of the production of IL-1 alpha and IL-2 and by the decreased expression of the CD25 (3).

During ovum pick-up, we aspirate all the FF and throw it away after ovum retrieval. This fluid normally enters the fallopian tubes while picking the ovum during ovulation in natural cycles and it reaches the uterine cavity as well and several studies suggested that it might have a crucial role in modifying uterine receptivity preparing the endometrium for the fertilized ovum arriving after 3 days as the TGF controls apoptosis, the IGF improves endometrial thickness and the immunosuppressive activity of the FF paves the way for the embryo to implant in the uterine cavity (4,5).

Actually Hunter study in 2007, provided circumstantial evidence for entry of follicular fluid into the Fallopian tubes, especially close to the time of ovulation, with the suggestion that such entry could modify the nature of endosalpingeal secretion and transudation. Thereafter, the spectrum of gonadal hormones in follicular fluid could be influencing uterine tissues in a local manner (5).

At the same time, it is a well known fact that implantation is the limiting step in IVF success , actually almost all IVF cycles succeed in offering fertilized ova giving rise to embryos at the different stages of development but unfortunately when we transfer them to the uterine cavity, 60% fail to implant.

Implantation is a complex initial step in the establishment of a successful pregnancy. Although embryo quality is an important determinant of implantation, temporally co-ordinated differentiation of endometrial cells to attain uterine receptivity and a synchronized dialogue between maternal and embryonic tissues are crucial. Optimizing endometrial receptivity in fertility treatment will improve success rate.

Several growth factors and cytokines appear to be involved in the process of implantation. Stem cell factor and its receptor c-kit regulate the progression and survival of germ cells and play an important role in follicular development. It is present in the follicular fluid however little information was available on the role of stem cell factor and its receptor in the process of blastocyst implantation. It was not until Mitsunari examined the expression of stem cell factor and its receptor in mouse embryos and in the stromal and epithelial cells of the uterine endometrium by reverse transcription -polymerase chain reaction . He illustrated that stem cell factor derived from endometrial cells and the implanting embryo exerts paracrine and autocrine action on the process of implantation by stimulating trophoblast outgrowth through its receptor c-kit (6).

Neglecting the importance of the follicular fluid and throwing it away during the process of IVF is actually a deviation from what happens in nature where the fallopian tube is intelligent enough to appreciate the value of this fluid and pick it up with the ovum.

That is why in this study, we want to mimic natural cycles and explore the benefits of flushing the uterine cavity with follicular fluid after ovum pick-up in improving implantation rates in ICSI cycles.

Materials and methods:

100 patients attending kasr El-Ainey IVF center preparing for ICSI cycles will be randomized into two groups.

In this prospective interventional study, the patients of both groups will receive the same induction protocol for controlled ovarian hyperstimulation which is the long protocol, our standard protocol in the center. Initial suppression of ovarian function with gonadotrophin releasing hormone agonist will start on day 21 of the preceeding cycle. Human menopausal gonadotrophin induction will start after confirmed ovarian down regulation by both laboratory investigations and ultrasound by daily intramuscular injection of 150-300 IU (Merional, IBSA) until at least 3 follicles reach 18 mm and serum estradiol level lies between 1000-4000 then 10000 IU, HCG is given.

Ovum pick-up is scheduled 35 hours later, where each follicle is aspirated in a separate tube and will be examined by the embryologist separately where:

* The follicular fluid from empty follicles will be discarded, only the FF from follicles where mature oocytes were retrieved will be used.
* The follicular fluid contaminated with blood will be discarded and would not be used, only the clear FF will be used.
* No flushing was used after oocyte aspiration in order not to interfere with the concentration of growth factors in the FF .

After explaining the procedure and taking informed consent from the patients:

2ml of clear follicular fluid will be injected in the uterine cavity to flush the endometrium through an IUI catheter after performing mock transfer in the study group.

While, in the control group, no flushing of the endometrial cavity with FF is done.

In both groups, embryo transfer will be carried out 2-3 days later according to the condition of the embryos and pregnancy test will be carried out 14 days later.

The protocol was approved by the review board at kasr el-Aini hospital; IVF center at Cairo university.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intra-cytoplasmic Sperm Injection Outcome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Follicular Fluid uterine cavity Implantation rates ICSI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

follicular fluid group

Follicular fluid group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is done.

Group Type EXPERIMENTAL

Follicular fluid

Intervention Type BIOLOGICAL

The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter

control group

Control group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is not done.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Follicular fluid

The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Maternal age ranges from 20-38 years.
2. Basal FSH \< 10 mIU/ml.
3. BMI \< 35 kg/m2.
4. Estradiol level \> 1000 at the day of HCG administration.
5. Estradiol level \< 4000 at the day of HCG administration.

Exclusion Criteria

1. Presence of Endometriosis.
2. Presence of Hydrosalpinx.
3. Presence of vaginal infection.
4. Presence of galactorrhea.
5. Presence of hormonal disorders.
6. Severe male factor infertility:

Sperm Count \< one million. Marked malformation
7. history of recurrent abortion.
Minimum Eligible Age

20 Years

Maximum Eligible Age

38 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nawara Mohamed Hashish

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nawara Mohamed Hashish

Assistant professor of Obstetrics and Gynecology

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nawara Mohamed Hashish, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Obstetrics and Gynecology,Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kasr El-Aini hospital

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

132012

Identifier Type: -

Identifier Source: org_study_id